Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations.

Kimuda MP, Noyes H, Mulindwa J, Enyaru J, Alibu VP, Sidibe I, Mumba Ngoyi D, Hertz-Fowler C, MacLeod A, Tastan Bishop Ö, Matovu E; TrypanoGEN Research Group as members of The H3Africa Consortium.

PLoS Negl Trop Dis. 2018 Feb 22;12(2):e0006300. doi: 10.1371/journal.pntd.0006300. eCollection 2018 Feb.

2.

Relationship between Trypanosoma brucei rhodesiense genetic diversity and clinical spectrum among sleeping sickness patients in Uganda.

Kato CD, Mugasa CM, Nanteza A, Matovu E, Alibu VP.

BMC Res Notes. 2017 Oct 27;10(1):518. doi: 10.1186/s13104-017-2860-x.

3.

Metabolic Profiling of Central Nervous System Disease in Trypanosoma brucei rhodesiense Infection.

Lamour SD, Alibu VP, Holmes E, Sternberg JM.

J Infect Dis. 2017 Dec 5;216(10):1273-1280. doi: 10.1093/infdis/jix466.

4.

Introducing the TrypanoGEN biobank: A valuable resource for the elimination of human African trypanosomiasis.

Ilboudo H, Noyes H, Mulindwa J, Kimuda MP, Koffi M, Kaboré JW, Ahouty B, Ngoyi DM, Fataki O, Simo G, Ofon E, Enyaru J, Chisi J, Kamoto K, Simuunza M, Alibu VP, Lejon V, Jamonneau V, Macleod A, Camara M, Bucheton B, Hertz-Fowler C, Sidibe I, Matovu E; TrypanoGEN Research Group as members of The H3Africa Consortium.

PLoS Negl Trop Dis. 2017 Jun 1;11(6):e0005438. doi: 10.1371/journal.pntd.0005438. eCollection 2017 Jun. No abstract available.

5.

APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis.

Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, Noyes H, Capewell P, Camara M, Milet J, Jamonneau V, Camara O, Matovu E, Bucheton B, MacLeod A.

Elife. 2017 May 24;6. pii: e25461. doi: 10.7554/eLife.25461.

6.

Population genetic structure and temporal stability among Trypanosoma brucei rhodesiense isolates in Uganda.

Kato CD, Alibu VP, Nanteza A, Mugasa CM, Matovu E.

Parasit Vectors. 2016 May 3;9:259. doi: 10.1186/s13071-016-1542-1.

7.

The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness.

Kato CD, Matovu E, Mugasa CM, Nanteza A, Alibu VP.

Allergy Asthma Clin Immunol. 2016 Jan 22;12:4. doi: 10.1186/s13223-016-0113-5. eCollection 2016. Review.

8.

Discovery of Infection Associated Metabolic Markers in Human African Trypanosomiasis.

Lamour SD, Gomez-Romero M, Vorkas PA, Alibu VP, Saric J, Holmes E, Sternberg JM.

PLoS Negl Trop Dis. 2015 Oct 27;9(10):e0004200. doi: 10.1371/journal.pntd.0004200. eCollection 2015.

9.

Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage Trypanosoma brucei rhodesiense Sleeping Sickness.

Kato CD, Alibu VP, Nanteza A, Mugasa CM, Matovu E.

PLoS Negl Trop Dis. 2015 Jun 19;9(6):e0003835. doi: 10.1371/journal.pntd.0003835. eCollection 2015 Jun.

10.

Community engagement strategies for genomic studies in Africa: a review of the literature.

Tindana P, de Vries J, Campbell M, Littler K, Seeley J, Marshall P, Troyer J, Ogundipe M, Alibu VP, Yakubu A, Parker M; as members of the H3A Working Group on Ethics.

BMC Med Ethics. 2015 Apr 12;16:24. doi: 10.1186/s12910-015-0014-z. Review.

11.

Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda.

Kato CD, Nanteza A, Mugasa C, Edyelu A, Matovu E, Alibu VP.

PLoS One. 2015 Feb 26;10(2):e0118370. doi: 10.1371/journal.pone.0118370. eCollection 2015.

12.

Phylogenetic analysis of rubella viruses identified in Uganda, 2003-2012.

Namuwulya P, Abernathy E, Bukenya H, Bwogi J, Tushabe P, Birungi M, Seguya R, Kabaliisa T, Alibu VP, Kayondo JK, Rivailler P, Icenogle J, Bakamutumaho B.

J Med Virol. 2014 Dec;86(12):2107-13. doi: 10.1002/jmv.23935. Epub 2014 Apr 4.

13.

Handling uncertainty in dynamic models: the pentose phosphate pathway in Trypanosoma brucei.

Kerkhoven EJ, Achcar F, Alibu VP, Burchmore RJ, Gilbert IH, Trybiło M, Driessen NN, Gilbert D, Breitling R, Bakker BM, Barrett MP.

PLoS Comput Biol. 2013;9(12):e1003371. doi: 10.1371/journal.pcbi.1003371. Epub 2013 Dec 5.

14.

N-Benzyloxycarbonyl-S-(2,4-dinitrophenyl)glutathione dibutyl diester is inhibitory to melarsoprol resistant cell lines overexpressing the T. bruceiMRPA transporter.

Alibu VP, Daunes S, D'Silva C.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4351-3. doi: 10.1016/j.bmcl.2013.05.086. Epub 2013 Jun 6.

PMID:
23791080
15.

Transketolase in Trypanosoma brucei.

Stoffel SA, Alibu VP, Hubert J, Ebikeme C, Portais JC, Bringaud F, Schweingruber ME, Barrett MP.

Mol Biochem Parasitol. 2011 Sep;179(1):1-7. doi: 10.1016/j.molbiopara.2011.04.006. Epub 2011 May 12.

PMID:
21570429
16.

Aryl phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal compounds.

Ruda GF, Wong PE, Alibu VP, Norval S, Read KD, Barrett MP, Gilbert IH.

J Med Chem. 2010 Aug 26;53(16):6071-8. doi: 10.1021/jm1004754.

17.

Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.

Ruda GF, Campbell G, Alibu VP, Barrett MP, Brenk R, Gilbert IH.

Bioorg Med Chem. 2010 Jul 15;18(14):5056-62. doi: 10.1016/j.bmc.2010.05.077. Epub 2010 Jun 9.

18.

A new erythrose 4-phosphate dehydrogenase coupled assay for transketolase.

Naula C, Alibu VP, Brock JM, Veitch NJ, Burchmore RJ, Barrett MP.

J Biochem Biophys Methods. 2008 Apr 24;70(6):1185-7. Epub 2007 Nov 12.

PMID:
18053578
19.

Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase.

Ruda GF, Alibu VP, Mitsos C, Bidet O, Kaiser M, Brun R, Barrett MP, Gilbert IH.

ChemMedChem. 2007 Aug;2(8):1169-80.

20.

Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance.

Lanteri CA, Stewart ML, Brock JM, Alibu VP, Meshnick SR, Tidwell RR, Barrett MP.

Mol Pharmacol. 2006 Nov;70(5):1585-92. Epub 2006 Aug 15.

21.

Characterization and developmentally regulated localization of the mitochondrial carrier protein homologue MCP6 from Trypanosoma brucei.

Colasante C, Alibu VP, Kirchberger S, Tjaden J, Clayton C, Voncken F.

Eukaryot Cell. 2006 Aug;5(8):1194-205.

22.

The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.

Alibu VP, Richter C, Voncken F, Marti G, Shahi S, Renggli CK, Seebeck T, Brun R, Clayton C.

Mol Biochem Parasitol. 2006 Mar;146(1):38-44. Epub 2005 Nov 18.

PMID:
16343658
23.

Down-regulating gene expression by RNA interference in Trypanosoma brucei.

Clayton CE, Estévez AM, Hartmann C, Alibu VP, Field M, Horn D.

Methods Mol Biol. 2005;309:39-60. No abstract available.

PMID:
15990397
24.

A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma brucei.

Alibu VP, Storm L, Haile S, Clayton C, Horn D.

Mol Biochem Parasitol. 2005 Jan;139(1):75-82.

PMID:
15610821
25.

Genomics research and malaria control: great expectations.

Alibu VP, Egwang TG.

PLoS Biol. 2003 Nov;1(2):E39. Epub 2003 Nov 17. No abstract available.

Supplemental Content

Loading ...
Support Center